Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01662804 | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01313936 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | completed | Phase 1 | 32 | University of California, San FranciscoOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT01462396 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors(STALLO) | completed | Phase 1 | 4 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01975116 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | completed | Phase 1 | 18 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 7, 2017 | clinicaltrials |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma | completed | Phase 1 | 18 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01132911 | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | completed | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01241162 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | completed | Phase 1 | 19 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02444884 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | completed | Phase 1 | 54 | Children's Oncology GroupNETWORK | 0 | Feb 9, 2016 | clinicaltrials |
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | completed | Phase 1 | 6 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01208454 | Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 2 | Nov 24, 2015 | clinicaltrials |
| NCT00450827 | Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | completed | Phase 1 / Phase 2 | 28 | United TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01598454 | Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides | completed | Phase 1 | 15 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Jul 29, 2015 | clinicaltrials |
| NCT00020150 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00003484 | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors | completed | Phase 1 | 21 | Darell D. Bigner, MD, PhDOTHER | 1 | Apr 23, 2015 | clinicaltrials |
| NCT01518413 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | completed | Phase 1 | 17 | HMeanyOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00003107 | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors | completed | Phase 1 | — | Indiana UniversityOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00003461 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | completed | Phase 1 / Phase 2 | — | Duke UniversityOTHER | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | completed | Phase 1 | 28 | Children's Oncology GroupNETWORK | 3 | Aug 8, 2014 | clinicaltrials |
| NCT00002740 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00003141 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | completed | Phase 1 | 94 | Children's Oncology GroupNETWORK | 3 | Mar 28, 2014 | clinicaltrials |
| NCT00070200 | Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | completed | Phase 1 | 31 | Children's Oncology GroupNETWORK | 2 | Feb 13, 2014 | clinicaltrials |
| NCT01048892 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | completed | Phase 1 | 22 | Children's Oncology GroupNETWORK | 1 | Jan 30, 2014 | clinicaltrials |
| NCT00028522 | R(+)XK469 in Treating Patients With Advanced Neuroblastoma | completed | Phase 1 | 85 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00450307 | Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | completed | Phase 1 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00075634 | Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00206388 | Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement | completed | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Aug 2, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 21, 2021source: clinicaltrials